Live·Verified funding discovery · 2026.2

874 grants · 19 open · 435 companies · 2640 concepts874 / 19 / 435 / 2640

△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA

Ratings

Eternal Search

Heroes

People whose work, funding, scientific leadership, and multiplier effects have shaped the longevity field.

Every score here rates one thing: longevity commitment. The role tags — scientist, investor, founder, and the rest — describe what a person does. We do not compute a separate rating for each tag.

Scoring AI engine · v0.9.0

RolesAll clinician communicator entrepreneur investor operator philanthropist populariser scientist self-experimenter

ThemesAll Destination Meta View Path Risk View Timeline

SortOverall Recently updated Future vision Scientific impact Capital deployed Strategic taste Field creation Bravery and conviction Multiplier effect

#ScoreHeroDimensionsScored

Aubrey de Greyv0.4.0

He made SENS-style damage repair a durable longevity agenda: 325 works, 4,733 citations, and public pushes for political attention. Not proof of therapies. Proof of agenda-setting.

populariserscientistphilanthropist

Alex Zhavoronkovv0.4.0

Zhavoronkov helped make AI drug discovery a serious longevity lane, not just conference vapor. His record is strongest in papers and Insilico’s aging-target work, not proven clinical wins.

populariserentrepreneurscientist

Steve Horvathv0.4.0

Horvath made aging measurable enough for others to argue with it. His epigenetic clocks became a test bed for longevity claims, including studies that find no rejuvenation when the hype fails.

scientistpopulariserphilanthropist

Matt Kaeberleinv0.4.0

Kaeberlein helped make mTOR, sirtuins, and rapamycin unavoidable in serious aging biology. Not a miracle salesman: his dog rapamycin trial found tolerability, not cardiac magic.

scientistpopulariserentrepreneur

Laura Demingv0.4.0

Deming helped drag longevity biotech from weird sidebar into fundable company-building, then put her current bet on reversible organ cryopreservation. Not proof of victory; proof of taste.

investorentrepreneurpopulariser

Bryan Johnsonv0.4.0

Johnson made longevity louder by turning his own protocol into media, a Don’t Die campaign, and an Rx platform. The hard evidence for field-building or scientific impact is thin.

self-experimenterpopulariserentrepreneur

Kai Micah Millsv0.4.0

Mills has pushed longevity toward cryonics infrastructure, not wellness theater, by building Cryopets and CryoDAO and publicly framing death as a technical problem. Evidence is thin; this is movement-building, not proven impact yet.

entrepreneurpopulariserinvestor

Nathan Chengv0.4.0

Cheng helped give longevity’s speculative edge an address: co-founding Longevity Biotech Fellowship and co-authoring a 2024 biostasis roadmap. The science is early; the agenda is concrete.

populariserentrepreneurinvestor

David Sinclairv0.4.0

Sinclair helped push longevity toward testable aging biology, including work on sex- and tissue-specific gene expression in aging mice. The company-founder story is thinner, so don’t gild it.

scientistentrepreneurpopulariser

Linus Petersv0.4.0

Peters pushed longevity as a public-legitimacy problem: if aging is treated as inevitable, talent and money stay away. That is advocacy, not proof of field impact.

popularisercommunicator

Martin Borch Jensenv0.4.0

Jensen helped make mitochondrial aging less hand-wavy: 76 works, 1,955 citations, and longevity org-building through Gordian and Norn. Real contribution, not life-extension magic.

entrepreneurphilanthropistpopulariser

Sergey Youngv0.4.0

Sergey Young helped put investor attention into longevity through Longevity Vision Fund and field-definition work. The record shows visibility, not proof of big deployed capital.

investorpopulariserphilanthropist

Adam Griesv0.4.0

Gries has helped make longevity look like a founder market, not just a lab topic. The hard proof is still thin: mostly Vitalist Bay convening claims and public vitalist signal, not documented capital or science.

populariserinvestor

Peter Diamandisv0.4.0

Diamandis helped push longevity toward AI-led health tracking and company-building, not lab-defining science. The evidence shows one aging-clock paper with 29 citations and thin disclosed capital.

entrepreneurpopulariserinvestor

Phil Newmanv0.4.0

Phil Newman’s longevity impact is translation, not miracle-making: he built longevity media platforms and brings a modest scientific record, with h-index 19 and 1,438 citations.

populariserentrepreneurcommunicator

Karl Pflegerv0.4.0

Pfleger helped make aging biotech more legible through AgingBiotech.info and coauthored a paper arguing that healthy life extension has far more public demand than sloppy surveys suggested.

populariserinvestorphilanthropist

Mikhail Batinv0.4.0

Batin helped make aging targets easier to inspect, mainly through Open Genes and AgeMeta. The citation signal is small, so this is infrastructure work, not a field-shaking discovery.

populariserscientist